NON-SMALL CELL LUNG CANCER (NSCLC)

This study tests whether adding olaparib to durvalumab can keep stage IV non-small cell lung cancer from progressing longer than durvalumab alone. About 400 adults whose cancer did not worsen after initial chemotherapy and durvalumab will receive either the combination or a place…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This early-phase trial tests a drug called HER3-DXd in people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The study includes patients with specific genetic changes (EGFR or KRAS mutations) whose cancer worsened after other treatments.…

This study tests three different immunotherapy drug combinations in people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. The goal is to see if adding another immune-boosting drug to the standard anti-PD1 therapy can better co…

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This study tests a new treatment called RP1, a modified virus that attacks cancer cells, alone or with the immunotherapy drug nivolumab. It includes adults with advanced melanoma, lung cancer, or other solid tumors that haven't responded to standard care. The goal is to see if th…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study tests whether adding a cholesterol-lowering drug (alirocumab) to an immunotherapy (cemiplimab) can help shrink tumors in people with advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. About 60 participants will receive the combinati…

This program provides expanded access to cemiplimab, an immunotherapy drug, for patients with certain solid tumors including non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. The goal is to make the treatment available to those who may not h…

This study tested whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 1,186 adults with metastatic NSCLC who had not re…

This early-stage study tests a new drug called furmonertinib in about 160 people with advanced or spreading non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to see if the drug is safe and can shrink tumors. Participants must have alre…

This study tests an experimental oral drug, IMM-1-104, in people with advanced solid tumors that have RAS mutations. The goal is to find a safe dose and see if it can shrink tumors, either alone or with other approved drugs. About 209 adults with pancreatic cancer, melanoma, or l…

This early-stage study tests a personalized cell therapy for people with advanced colorectal, pancreatic, or lung cancers that have a specific KRAS mutation. The treatment uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to ch…

This study tests whether adding a precise type of radiation (SABR) to the targeted drug osimertinib can help people with advanced EGFR-mutant lung cancer live longer without their disease getting worse. About 41 adults with this specific genetic type of lung cancer will receive b…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer that has a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will …

This program provides early access to telisotuzumab vedotin, an investigational drug for non-small cell lung cancer (NSCLC), before it is officially approved. It is for patients who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must de…

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system target cancer proteins MAGE-A3 and NY-ESO-1. About 15 adults with advanced non-small cell lung cancer or squamous esophageal cancer will receive the vaccines alongside thei…

This study compares a new drug, MK-2870, to standard chemotherapy (docetaxel or pemetrexed) in 556 people with advanced or metastatic non-small cell lung cancer that has specific genetic changes (EGFR mutations or others) and has already been treated. The goal is to see if MK-287…

This program provides access to the drug ceritinib (LDK378) for patients with serious ALK-positive tumors, including non-small cell lung cancer, who have no other treatment options and cannot join a clinical trial. It is designed for individual patients whose doctors request the …

This study tests a new drug, MK-2870, against standard chemotherapy in 520 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has worsened after targeted therapy. The main goal is to see if MK-2870 helps people live longer. Participants are…

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors (like lung, bladder, or breast cancer). The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be…

This study follows 50 adults with ALK-positive non-small cell lung cancer who are taking brigatinib as their first treatment. Researchers want to see how long the cancer stays under control and how many patients respond to the drug. No new treatment is given; data is collected du…

This study compares two ways of doing a lung biopsy (EBUS) for people with known or suspected non-small cell lung cancer. In one group, a cytotechnologist checks the tissue sample on-site during the procedure to give feedback. In the other group, no on-site check is done. The goa…

This study looks at whether a custom blood test, based on each patient's tumor DNA, can detect if early-stage non-small cell lung cancer comes back after surgery. Researchers will follow 450 patients and compare the test's timing with standard imaging like CT scans. The goal is t…

This study looks at how long Chinese patients with ALK-positive advanced lung cancer stay on brigatinib treatment in real-world settings. Researchers will also track cancer progression and response to the drug. About 154 participants are included, and the study simply observes th…

This study is observing how well a combination of two immunotherapy drugs (nivolumab and ipilimumab) works for people with advanced non-small cell lung cancer in Italy. Researchers are collecting data from 404 patients to understand real-world outcomes, side effects, and treatmen…

This study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one …

This study follows 160 adults with lung cancer to see how changes in muscle mass, strength, and function relate to treatment side effects, quality of life, and survival. Researchers want to understand why some patients struggle to complete their cancer therapy. The goal is to use…

This study observes 300 adults with advanced non-small cell lung cancer whose tumors have very low PD-L1 levels (below 1%). Researchers are tracking side effects and healthcare use from first-line treatments like nivolumab plus ipilimumab, with or without chemotherapy. The goal i…